Mode
Text Size
Log in / Sign up
N/A N=221 Treatment

Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence

Urinary Incontinence

Enrolled (actual)
221
Serious AEs
1.2%
Results posted
Jun 2018
Primary outcome: Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ACT (Adjustable Continence Therapy) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Uromedica
Primary completion
Jul 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Change of Stamey Grade From Baseline to 12 Months.
-1.17 <0.001 sig
SECONDARY
Incontinence Quality of Life (IQoL) Questionnaire
28.63
SECONDARY
Incontinence Impact Questionnaire (IIQ-7)
-26.53
SECONDARY
Urinary Distress Inventory (UDI-6)
-22.66
SECONDARY
Number of Incontinence Episodes Per Day (Voiding Diary)
-2.76
SECONDARY
Number of Pads Changed Per Day (Voiding Diary)
-1.59
SECONDARY
Provocative Pad Weight
-31.03

Summary

The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence. The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether the patients demonstrate at least a one-grade (mean) reduction in the Stamey score at 12 months.

Eligibility Criteria

Inclusion Criteria

  • Women
  • 18 years or older
  • Diagnosed with stress urinary incontinence with or without urethral hypermobility
  • Willing to sign informed consent
  • Candidates for surgical intervention for stress incontinence
  • Negative urinalysis or urine culture within 2 weeks of implantation
  • Normal cystourethroscopy
  • Failed at least 6 months of previous treatments for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc.)
  • May have failed suspension or sling procedures

Exclusion Criteria

  • Pregnant or lactating
  • Life expectancy of less than one year
  • Insulin dependant diabetic
  • Auto-immune disease
  • Undergoing radiation therapy
  • Active urinary tract infection
  • Detrusor instability refractory to meds
  • Reduced bladder compliance
  • Significant bladder residual >100mls
  • Bladder cancer
  • Unsuccessfully treated bladder stones
  • Current urethral stricture preventing the passage of a 24 French endoscope
  • Neurogenic bladder
  • Uncorrected rectocele, cystocele, urethrocele, enterocele or pelvic prolapse of Grade 3 or higher
  • Prior pelvic radiotherapy
  • Artificial urinary sphincter implanted
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00113555). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search